The American laboratory Eli Lilly obtained in the third quarter a net profit of 6.451 billion dollars (5.787 billion euros), which represents an increase of 15.5% compared with the same period of 2025.
Between July and September, the pharmaceutical company's total revenue rose by 39%, to 24.397 billion dollars (21.887 billion euros), while operating expenses increased by 64%, reaching 11.856 billion dollars (10.636 billion euros).
The United States remains the main market for Eli Lilly, with revenue of 15.136 billion dollars (13.579 billion euros), 34% more. In Europe, revenue amounted to 4.459 billion dollars (4.000 billion euros), which represents an increase of 28%.
In Japan, the company brought in 648 million dollars (581 million euros), 16% more, while in China the figure stood at 947 million dollars (850 million euros), 69% higher. In the rest of the markets, Eli Lilly generated 3.206 billion dollars (2.876 billion euros), 90% more than a year earlier.
The main boost comes from the drugs Mounjaro --for type 2 diabetes-- and Zepbound --indicated for chronic weight management--. Mounjaro contributed 10.723 billion dollars (9.620 billion euros), 65% more year-on-year, while Zepbound reached 5.352 billion dollars (4.801 billion euros), 49% more, so that between both they comfortably exceeded half of the group's revenue.
In the first nine months of the fiscal year, Eli Lilly recorded cumulative revenue of 67.170 billion dollars (60.266 billion euros), 46% more than in the same period of the previous year.
The company has revised upward its revenue forecasts for the full year and now expects to be in a range of between 91.000 and 92.000 billion dollars (81.647 and 82.545 billion euros). However, it has cut its earnings per share estimates, which are placed in a range of between 35 and 36 dollars (31,40 and 32,30 euros) per share.
"Lilly has had another solid quarter, exceeding our previous expectations and allowing us to raise our forecasts for the full year. (...) Lilly is executing its strategy successfully across the entire value chain, and our potential to generate a positive impact on human health continues to grow," emphasized the president and chief executive officer of Eli Lilly, David Ricks.